| 2.96 -0.2 (-6.33%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.61 | 1-year : | 5.38 |
| Resists | First : | 3.95 | Second : | 4.61 |
| Pivot price | 2.36  |
|||
| Supports | First : | 2.31 | Second : | 1.3 |
| MAs | MA(5) : | 3.31  |
MA(20) : | 2.12 |
| MA(100) : | 1.62 |
MA(250) : | 1.59 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 71.9 |
D(3) : | 77.7 |
| RSI | RSI(14): 66.3 |
|||
| 52-week | High : | 3.95 | Low : | 1 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ZNTL ] has closed below upper band by 34.3%. Bollinger Bands are 597.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.26 - 3.27 | 3.27 - 3.29 |
| Low: | 2.88 - 2.9 | 2.9 - 2.92 |
| Close: | 2.92 - 2.96 | 2.96 - 2.99 |
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Sat, 10 Jan 2026
Zentalis Pharmaceuticals Surges with Azenosertib Developments - timothysykes.com
Thu, 08 Jan 2026
Walters group buys Zentalis Pharmaceuticals (ZNTL) shares for $7.7m - Investing.com
Wed, 07 Jan 2026
Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st
Wed, 07 Jan 2026
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Surges 28% Yet Its Low P/S Is No Reason For Excitement - simplywall.st
Tue, 06 Jan 2026
Zentalis Pharmaceuticals Provides Corporate Update and - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 13.5 (%) |
| Held by Institutions | 68 (%) |
| Shares Short | 5,500 (K) |
| Shares Short P.Month | 5,080 (K) |
| EPS | -2.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.5 |
| Profit Margin | 0 % |
| Operating Margin | -567.8 % |
| Return on Assets (ttm) | -24.6 % |
| Return on Equity (ttm) | -49.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.37 |
| Sales Per Share | 0.37 |
| EBITDA (p.s.) | -2.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -134 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -1.43 |
| PEG Ratio | 0 |
| Price to Book value | 0.84 |
| Price to Sales | 7.96 |
| Price to Cash Flow | -1.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|